Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Anna M G Pasmooij"'
Autor:
Marijn Muurling, Anna M G Pasmooij, Ivan Koychev, Dora Roik, Lutz Froelich, Emilia Schwertner, Dorota Religa, Carla Abdelnour, Mercè Boada, Monica Almici, Samantha Galluzzi, Sandra Cardoso, Alexandre de Mendonça, Andrew P Owens, Sajini Kuruppu, Martha Therese Gjestsen, Ioulietta Lazarou, Mara Gkioka, Magda Tsolaki, Ana Diaz, Dianne Gove, Pieter Jelle Visser, Dag Aarsland, Federica Lucivero, Casper de Boer, RADAR-AD Consortium
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0294797 (2023)
[This corrects the article DOI: 10.1371/journal.pone.0285807.].
Externí odkaz:
https://doaj.org/article/bd39a7038b4346209d0f2bc37f15046c
Autor:
Marijn Muurling, Anna M G Pasmooij, Ivan Koychev, Dora Roik, Lutz Froelich, Emilia Schwertner, Dorota Religa, Carla Abdelnour, Mercè Boada, Monica Almici, Samantha Galluzzi, Sandra Cardoso, Alexandre de Mendonça, Andrew P Owens, Sajini Kuruppu, Martha Therese Gjestsen, Ioulietta Lazarou, Mara Gkioka, Magda Tsolaki, Ana Diaz, Dianne Gove, Pieter Jelle Visser, Dag Aarsland, Federica Lucivero, Casper de Boer, RADAR-AD Consortium
Publikováno v:
PLoS ONE, Vol 18, Iss 7, p e0285807 (2023)
IntroductionClinical research with remote monitoring technologies (RMTs) has multiple advantages over standard paper-pencil tests, but also raises several ethical concerns. While several studies have addressed the issue of governance of big data in c
Externí odkaz:
https://doaj.org/article/192ad7c5d4424e03a291c8937325bef4
Autor:
Peter C van den Akker, Anna M G Pasmooij, Hans Joenje, Robert M W Hofstra, Gerard J Te Meerman, Marcel F Jonkman
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0192994 (2018)
Revertant mosaicism, or "natural gene therapy", is the phenomenon in which germline mutations are corrected by somatic events. In recent years, revertant mosaicism has been identified in all major types of epidermolysis bullosa, the group of heritabl
Externí odkaz:
https://doaj.org/article/3024b096775248879066e7fa1344efa7
Autor:
Marko J, Kallio, Viktoriia, Starokozhko, Eleonora, Agricola, Manja, Burggraf, Anne, Heß, Wolfgang, Ballensiefen, Wiebke, Löbker, Yoana, Nuevo, Anna M G, Pasmooij, Peter G M, Mol
Publikováno v:
Clinical Pharmacology and Therapeutics, 113(2), 349-359. Nature Publishing Group
Important discoveries by academic drug developers hold the promise of bringing innovative treatments that address unmet medical needs to the market. However, the drug development process has proved to be challenging and demanding for academic researc
Autor:
Eva W H Korte, Tobias Welponer, Jan Kottner, Sjoukje van der Werf, Peter C van den Akker, Barbara Horváth, Dimitra Kiritsi, Martin Laimer, Anna M G Pasmooij, Verena Wally, Maria C Bolling
Publikováno v:
British Journal of Dermatology.
Background Epidermolysis bullosa (EB) is a rare, genetically and clinically heterogeneous group of skin fragility disorders. No cure is currently available, but many novel and repurposed treatments are upcoming. For adequate evaluation and comparison
Autor:
Viktoriia Starokozhko, Anne Heß, Wiebke Löbker, Wolfgang Ballensiefen, Eleonora Agricola, Bettina Ziegele, Marko J. Kallio, Laurence O’Dwyer, Yoana Nuevo, Peter G. M. Mol, Anna M. G. Pasmooij
Publikováno v:
Nature Reviews Drug Discovery. 22:251-252
Autor:
Jorn, Mulder, Odile C, van Stuijvenberg, Paula B, van Hennik, Emile E, Voest, Anna M G, Pasmooij, Violeta, Stoyanova-Beninska, Anthonius, de Boer
Publikováno v:
Frontiers in Medicine. 9
There are currently four anti-cancer medicinal products approved for a tissue-agnostic indication. This is an indication based on a common biological characteristic rather than the tissue of origin. To date, the regulatory experience with tissue-agno
Publikováno v:
Expert review of molecular diagnostics. 22(5)
The In Vitro Diagnostics Regulation 2017/746 (IVDR) coming into force from May 2022, creates the first European regulatory recognition for biomarker tests linked to medicinal products, so-called companion diagnostics (CDx). Since the introduction of
Publikováno v:
Frontiers in Medicine, 9
With the implementation of the new EU regulation on in vitro diagnostics (IVDR) in May 2022, notified bodies will be required to assess Companion Diagnostics (CDx). The EMA and national medicines agencies will be consulted on the performance and safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0253c66505a8f93e2cb96cddc98bcd29
http://hdl.handle.net/2066/250646
http://hdl.handle.net/2066/250646
Autor:
Marieke J. H. J. Dekker 1, Pieter Stolk2 and Anna M. G. Pasmooij 1* on behalf of the RADAR-AD†
Aims: Recently, the use of novel remote monitoring technologies (RMTs) in trials has gained much interest. To facilitate regulatory learning, we evaluated qualification opinions (QOs) and advices (QAs) and scientific advices (SAs) of the Committee fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::629bd8b1e821716b1130d00e327b5888